Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of February 2020, specifically dated February 13, 2020. The registrant is a foreign private issuer based in Petach-Tikva, Israel, focused on biopharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-driven filing and does not contain financial statements or performance metrics.
Material Changes and Corporate Events
- Regulatory Submission: The Company submitted the protocol design and registration plan for its pivotal Phase III liver cancer trial to the European Medicines Agency (EMA) Committee for Medicinal Product and Human Use (CHMP).
- Shareholder Meeting Postponement: The special meeting of shareholders originally scheduled for February 13, 2020, was adjourned for one week. The meeting is reconvened for Thursday, February 20, 2020, at 3:00 p.m. Israel time at the Company's offices.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the operational updates regarding the clinical trial submission and the rescheduling of the shareholder meeting.
Key Facts for Investor Verification
- Confirm the status of the Phase III liver cancer trial protocol submission with the EMA CHMP.
- Verify the agenda and voting outcomes of the rescheduled special shareholder meeting on February 20, 2020.
- Review the attached press release (Exhibit 99.1) for additional details on the clinical trial design not included in the summary text.